Wilson Therapeutics

BioArctic hires Anders Martin-Löf as new CFO

Retrieved on: 
Tuesday, February 28, 2023

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO.

Key Points: 
  • STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO.
  • Anders Martin-Löf brings broad experience from similar roles at companies such as Oncopeptides, Wilson Therapeutics, RaySearch and most recently at A3P Biomedical.
  • Current CFO Jan Mattsson will remain in his role until Anders Martin-Löf takes up his position and will then move to a newly established role as VP Finance.
  • Anders Martin-Löf will join BioArctic on June 1 at the latest, and will be part of the company's group management.

BioArctic hires Anders Martin-Löf as new CFO

Retrieved on: 
Tuesday, February 28, 2023

STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO.

Key Points: 
  • STOCKHOLM, Feb. 28, 2023 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that the company has recruited Anders Martin-Löf as its new CFO.
  • Anders Martin-Löf brings broad experience from similar roles at companies such as Oncopeptides, Wilson Therapeutics, RaySearch and most recently at A3P Biomedical.
  • Current CFO Jan Mattsson will remain in his role until Anders Martin-Löf takes up his position and will then move to a newly established role as VP Finance.
  • Anders Martin-Löf will join BioArctic on June 1 at the latest, and will be part of the company's group management.

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.

Key Points: 
  • Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company's clinical development, regulatory and medical affairs teams.
  • Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys.
  • As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3.
  • Dr. Thomas Sciascia, MD, the co-founder of Trevi Therapeutics, previously served as Trevi's Chief Medical Officer and will be transitioning to Chief Science Officer.

Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

Retrieved on: 
Wednesday, March 16, 2022

Kither Biotech Raises 18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer

Key Points: 
  • Kither Biotech Raises 18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
    International syndicate of new investors including Claris Ventures, 2 Invest, 3B Future Health Fund and Alef 6, with continued support from existing investors
    Turin, Italy, 16 March 2022 Kither Biotech (Kither or the Company), a biopharmaceutical company developing novel therapies for rare respiratory diseases, today announces that it has raised 18.5 million in a Series B financing round and has appointed current Board Member Dr. Vincent Metzler as Chief Executive Officer.
  • Kither also announces today the appointment of Dr. Vincent Metzler as Chief Executive Officer, while current CEO Marco Kevin Malisani transitions to the role of Chief Financial Officer and remains a member of the Board of Directors.
  • Dr. Vincent Metzler, CEO at Kither Biotech, commented: Kither is committed to developing transformative therapies for patients living with rare pulmonary diseases.
  • Heikki Lanckriet, newly appointed Non-executive Director at Kither Biotech said: I am excited to join the Kither Biotech board of directors at such an exciting phase.

Healthcap Strengthens Senior Team

Retrieved on: 
Thursday, October 7, 2021

Mrten became a Partner at HealthCap in 2010 and has been instrumental in many of HealthCaps most successful investments including Ultragenyx and Wilson Therapeutics.

Key Points: 
  • Mrten became a Partner at HealthCap in 2010 and has been instrumental in many of HealthCaps most successful investments including Ultragenyx and Wilson Therapeutics.
  • Kristina Ekberghas joined HealthCap as Partner and General Counsel as of September 2021.
  • Georg was recently appointed CEO of Tribune Therapeutics AB, an Oslo based company created by HealthCap, Novo Seeds and its scientific founders.
  • Bjrn Odlander, Founding Partner of HealthCap, said: "This year HealthCap celebrates 25 years of operations.

Healthcap Strengthens Senior Team

Retrieved on: 
Thursday, October 7, 2021

STOCKHOLM, Oct. 7, 2021 /PRNewswire/ -- HealthCap, a leading European life sciences venture capital firm, is delighted to announce that Dr. Mårten Steen, MD, PhD, has been appointed Co-Managing Partner alongside Founding Partner Björn Odlander.

Key Points: 
  • Mrten became a Partner at HealthCap in 2010 and has been instrumental in many of HealthCaps most successful investments including Ultragenyx and Wilson Therapeutics.
  • Kristina Ekberghas joined HealthCap as Partner and General Counsel as of September 2021.
  • Georg was recently appointed CEO of Tribune Therapeutics AB, an Oslo based company created by HealthCap, Novo Seeds and its scientific founders.
  • Bjrn Odlander, Founding Partner of HealthCap, said: "This year HealthCap celebrates 25 years of operations.

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2021 Financial Results

Retrieved on: 
Thursday, July 29, 2021

SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after theU.S.financial markets close onThursday, August 5, 2021.

Key Points: 
  • SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after theU.S.financial markets close onThursday, August 5, 2021.
  • ET) to provide a comprehensive business update and discuss the Companys financial results.
  • Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.
  • Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.

Oncternal Therapeutics to Report Fourth Quarter 2020 Financial Results and Provide Business Update

Retrieved on: 
Thursday, March 4, 2021

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021.

Key Points: 
  • SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report fourth quarter and full year 2020 financial results after the U.S. financial markets close on Thursday, March 11, 2021.
  • ET) to discuss the Companys financial results and provide a comprehensive business update.
  • Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need.
  • Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression.

LifeMine Therapeutics Announces $50 Million Series B Financing

Retrieved on: 
Thursday, January 7, 2021

LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investors.

Key Points: 
  • LifeMine Therapeutics Inc., a biopharmaceutical company reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics, today announced a $50 million Series B financing from leading life sciences investors.
  • Proceeds from the Series B financing will allow the Company to accelerate and expand its drug discovery efforts, as well as strategically advance select pipeline programs toward clinical development.
  • With the completion of the Series B financing, LifeMine has now raised more than $120 million from leading life science investors since the Companys founding in 2017.
  • LifeMine Therapeutics is reinventing drug discovery by mining fungal biodiversity to develop mechanistically and structurally novel therapeutics to address previously intractable therapeutic challenges.

Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock

Retrieved on: 
Monday, January 4, 2021

SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock.

Key Points: 
  • SAN DIEGO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the Company or Fate Therapeutics) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering of $350 million of shares of common stock.
  • In connection with the offering, Fate Therapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $52.5 million of shares of common stock offered in the public offering.
  • All shares of common stock to be sold in the offering will be offered by Fate Therapeutics.
  • The securities described above are being offered by Fate Therapeutics pursuant to an automatic shelf registration statement on Form S-3 (File No.